TIGIT and chronic myelogenous leukemia, BCR-ABL1 positive: As such, immune-checkpoint inhibitors targeting TIGIT and TIM3 are interesting molecular targets to induce more potent NK cell engagement against CML cells, but further studies are needed with larger cohort of primary CML cells.